IMM-H007

IMM-H007 (WS070117) is an orally active and potent AMPK (AMP-activated protein kinase) activator and TGFβ1 (transforming growth factor β1) antagonist. IMM-H007 has protective effects in cardiovascular diseases via activation of AMPK. IMM-H007 negatively regulates endothelium inflammation through inactivating NF-κB and JNK/AP1 signaling. IMM-H007 inhibits ABCA1 degradation. IMM-H007 resolves hepatic steatosis in HFD-fed hamsters by the regulation of lipid metabolism. IMM-H007 can be used for the research of nonalcoholic fatty liver disease (NAFLD) and inflammatory atherosclerosis[1][2][3].

Product Specifications

CAS Number

[1221412-23-2]

Product Name Alternative

WS070117

UNSPSC

12352005

Target

AMPK; AP-1; JNK; NF-κB; TGF-β Receptor

Type

Reference compound

Related Pathways

Epigenetics; Immunology/Inflammation; MAPK/ERK Pathway; NF-κB; PI3K/Akt/mTOR; TGF-beta/Smad

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/imm-h007.html

Purity

97.69

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

CC(O[C@H]1[C@@](N2C3=NC=NC(NC4=CC(O)=CC=C4)=C3N=C2)([H])O[C@@H]([C@H]1OC(C)=O)COC(C)=O)=O

Molecular Formula

C22H23N5O8

Molecular Weight

485.45

References & Citations

[1]Yu J, et al. IMM-H007, a novel small molecule inhibitor for atherosclerosis, represses endothelium inflammation by regulating the activity of NF-κB and JNK/AP1 signaling. Toxicol Appl Pharmacol. 2019 Oct 15;381:114732.|[2]Shi H, et al. IMM-H007, a new therapeutic candidate for nonalcoholic fatty liver disease, improves hepatic steatosis in hamsters fed a high-fat diet. FEBS Open Bio. 2017 Aug 29;7 (9) :1379-1391.|[3]Wang SX, et al. IMM-H007 attenuates isoprenaline-induced cardiac fibrosis through targeting TGFβ1 signaling pathway. Acta Pharmacol Sin. 2022 Mar 30.